CVS Health (CVS)

• Market cap: $55.5B
• 1 day: -0.83%
• 5 days: -0.52%
• 1 month: -25.32%
• 3 months: -29.83%
• 6 months: -24.13%
• Year to date: -45.43%
• 1 year: -45.43%
• 5 years: -40.14%
• 10 years: -54.76%
• Sector: Consumer Discretionary
• Industry: Drug Stores & Proprietary Stores

About: CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

Employees: 300,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22% more call options, than puts

Call options by funds: $1.79B | Put options by funds: $1.47B

2% more capital invested

Capital invested by funds: $62.8B [Q2] → $63.8B (+$1.03B) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 27 [Q2] → 27 (+0) [Q3]

3.58% less ownership

Funds ownership: 84.54% [Q2] → 80.96% (-3.58%) [Q3]

4% less funds holding

Funds holding: 1,869 [Q2] → 1,796 (-73) [Q3]

32% less first-time investments, than exits

New positions opened: 154 | Existing positions closed: 227

52% less repeat investments, than reductions

Existing positions increased: 477 | Existing positions reduced: 991

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $58 31% upside
• Avg. target: $67 52% upside
• High target: $80 81% upside

11 analyst ratings

• positive: 9 82%
• neutral: 2 18%
• negative: 0 0%

Deutsche Bank George Hill 60% 1-year accuracy 6 / 10 met price target	50% upside $66	Buy Upgraded	3 Dec 2024
TD Cowen Charles Ryhee 29% 1-year accuracy 2 / 7 met price target	81% upside $80	Buy Maintained	25 Nov 2024
Piper Sandler Jessica Tassan 24% 1-year accuracy 5 / 21 met price target	45% upside $64	Overweight Maintained	25 Nov 2024
Truist Securities David Macdonald 55% 1-year accuracy 48 / 87 met price target	52% upside $67	Buy Reiterated	20 Nov 2024
Wells Fargo Stephen Baxter 20% 1-year accuracy 8 / 40 met price target	50% upside $66	Overweight Upgraded	18 Nov 2024